Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?

被引：3
|
作者：
Kourie, Hampig Raphael [1 ]
Awada, Gil [2 ]
Awada, Ahmad Hussein [1 ]
机构：
[1] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium
[2] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Brussels, Belgium
来源：
FUTURE ONCOLOGY | 2016年 / 12卷 / 04期
关键词：
cancer; checkpoint inhibitors; clinical trial; diagnosis; future; immunotherapies; ipilimumab; nivolumab; pembrolizumab; unknown primary tumor; NIVOLUMAB; ANTI-PD-1; SAFETY;
D O I：
10.2217/fon.15.329
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：429 / 431
页数：3
相关论文
共 50 条
  • [31] Future directions in immune-checkpoint inhibitors in NSCLC
    Hayashi, Hidetoshi
    CANCER SCIENCE, 2018, 109 : 1225 - 1225
  • [32] Primary Adrenal Insufficiency Secondary to Immune Checkpoint Inhibitors
    Bai, Joti
    Kohli, Jatinder
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 575 - 576
  • [33] Mechanisms of primary resistance to immune checkpoint inhibitors in Melanoma
    Moogk, Duane
    Wang, Lin
    Li, Kaitao
    Yuan, Zhou
    Zhong, Shi
    Yu, Zhiya
    Liadi, Ivan
    Rittase, William
    Fang, Victoria
    Dougherty, Janna
    Perez-Garcia, Arianne
    Varadarajan, Navin
    Restifo, Nicholas P.
    Frey, Alan
    Osman, Iman
    Weber, Jeff
    Zhu, Cheng
    Krogsgaard, Michelle
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17
  • [34] Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC
    Gomatou, Georgia
    Charpidou, Andriani
    Li, Peifeng
    Syrigos, Nikolaos
    Gkiozos, Ioannis
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, : 1426 - 1437
  • [35] Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
    Ouyang, Peng
    Wang, Lijuan
    Wu, Jianlong
    Tian, Yao
    Chen, Caiyun
    Li, Dengsheng
    Yao, Zengxi
    Chen, Ruichang
    Xiang, Guoan
    Gong, Jin
    Bao, Zhen
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [36] Microfluidic Model for Evaluation of Immune Checkpoint Inhibitors in Human Tumors
    Beckwith, Ashley L.
    Velasquez-Garcia, Luis F.
    Borenstein, Jeffrey T.
    ADVANCED HEALTHCARE MATERIALS, 2019, 8 (11)
  • [37] Hepatitis C and tumors: immune checkpoint inhibitors safe and effective?
    Simon, Annika
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2024, 62 (02): : 156 - 158
  • [38] Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018
    Kabir, Tanvir F.
    Chauhan, Aman
    Anthony, Lowell
    Hildebrandt, Gerhard C.
    OCHSNER JOURNAL, 2018, 18 (04): : 370 - 376
  • [39] Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review
    Yang, Kaili
    Li, Jiarui
    Sun, Zhao
    Zhao, Lin
    Bai, Chunmei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [40] What is the optimal duration of immune checkpoint inhibitors in malignant tumors?
    Yin, Jiaxin
    Song, Yuxiao
    Tang, Jiazhuo
    Zhang, Bicheng
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345